ABSTRACT
Introduction
Lung cancer remains one of the most frequent causes of cancer death worldwide. Most patients will be diagnosed with NSCLC, and the number with early-stage or localized disease is expected to rise over the next several years due to increasing use of computed tomographic (CT) screening. 1 Although the treatment of choice for early-stage NSCLC remains lobectomy, many patients are not candidates due to comorbidities. 2 Stereotactic body radiation therapy (SBRT) has emerged as the preferred treatment for these medically inoperable patients with primary tumor control rates higher than those with conventionally fractionated radiation in randomized and population-based comparisons. 3, 4 SBRT delivers highly precise and biologically potent doses of radiation with a sharp drop-off of dose from the target. The location of this dose gradient determines toxicity but not efficacy. Indiana University was the first to show that the treatment of central and perihilar tumors resulted in a higher risk of severe toxicity than did the treatment of peripheral tumors (27% versus 10%). 5 This central region was defined as within 2 cm of the proximal bronchial tree and since then patients with tumors in this region have been excluded from most SBRT trials. Here we report the safety and efficacy of dose-escalated SBRT for tumors in this central region on a prospective phase I/II institutional clinical trial.
Methods

Patient Eligibility
All patients signed informed consent to participate in this institutional review board-approved singleinstitution prospective phase I/II study. Patients with histologically confirmed NSCLC were enrolled if the tumor was 7 cm or less in diameter and was within one of the three following central chest locations: (1) within or touching the zone of the proximal bronchial tree, (2) within 5 mm or invading the mediastinal pleura; and (3) within 5 mm or invading the parietal pericardium. The zone of the proximal bronchial tree was defined as per the Radiation Therapy Oncology Group (RTOG) as a volume 2 cm in all directions around the carina, right and left main bronchi, right and left upper lobe bronchi, bronchus intermedius, right middle lobe bronchus, lingular bronchus, and right and left lower lobe bronchus.
All patients were staged with a CT scan of the chest, a positron-emission tomography scan, pulmonary function tests, and either brain magnetic resonance imaging or head CT with contrast. Patients with hilar or mediastinal lymph nodes 1 cm or less in smallest diameter with no abnormal uptake on positron-emission tomography were considered eligible. Patients were without active infection, older than the age of 18 years, and had a Zubrod performance status of 0-2. Patients with synchronous primary cancers or prior malignancies other than nonmelanoma skin cancer in the past 2 years were excluded. Patients with previous lung or mediastinal radiation therapy were also excluded. No concomitant antineoplastic therapy was allowed.
All patients were deemed medically inoperable. Patients were considered medically inoperable if they met any one of the following criteria: baseline forced expiratory volume in the forced expiratory volume in 1 second (FEV 1 ) of less than 40% predicted, predicted postoperative FEV 1 of less than 30% predicted, carbon monoxide diffusing capacity of less than 40% predicted, baseline hypoxemia or hypercapnia, severe pulmonary hypertension; diabetes mellitus with end-organ damage; severe cerebral, cardiovascular, or peripheral vascular disease; or severe chronic heart disease.
Treatment Planning
Patients were simulated with CT using fourdimensional imaging and with intravenous contrast, unless the patient had an allergy or renal insufficiency. Axial CT acquisitions were performed with spacing 3 mm or less between slices. Patients generally were immobilized with an alpha cradle and abdominal compression. The target lesion was outlined and designated as the gross tumor volume, generally using CT pulmonary windows; however, soft-tissue CT windows with contrast were used to avoid inclusion of adjacent vessels, atelectasis, and other mediastinal or chest wall structures in the gross tumor volume. Four-dimensional CT scans were then used to generate a maximum intensity projection from which an internal target volume (ITV) was created. A planning target volume (PTV) was created by expanding the ITV by 5 mm in all directions.
Typically either two to three arcs or seven to 10 static beams with roughly equal weighting were used. With static beams, nonopposing, noncoplanar beam arrangements were preferred. Isodose lines covering the PTV were typically 60% to 90%. Arc plans were optimized to include a "hot" center of 120% on the ITV. All plans were calculated using heterogeneity correction.
At least 95% of the PTV had to be covered by prescription dose, and at least 99% of the PTV received 90% of the prescription dose. The cumulative volume of all tissues outside the PTV receiving 105% or more of the prescription dose was limited to 15% of the PTV volume. The ratio of the volume of the prescription isodose to the volume of the PTV (conformality index) was less than 1.2, although was not a requirement for tumors less than 2.5 cm in axial diameter or less than 1.5 cm craniocaudal dimension. The ratio of the volume receiving 50% of the prescription dose to the volume of the PTV was less than 3.9, with minor deviations less than 4.1. The percent of lung receiving 20 Gy (V20) or more was ideally limited to less than 10%, although minor deviations to 15% were allowed. Table 1 lists the guidelines for maximum dose to a point or volume within critical organs. The spinal cord limit was absolute. For all others, exceeding limits by 2.5% was a minor violation, and exceeding by 5% was a major violation. The phase 1 portion consisted of four radiation dose levels using 5 fractions each. Dose levels were 9, 10, 11, and 12 Gy per fraction.
Follow-up and Endpoints
Patients were evaluated for toxicity according to Common Terminology Criteria for Adverse Events (CTCAE version 4.0) each day of treatment and at 6 and 12 weeks post-treatment. Thereafter, patients were seen every 3 months for the first 2 years and every 6 months for the next 2 years. Adverse events grade 3 or greater were tracked. CT scans of the chest, liver, and adrenals were performed at 6 weeks post-treatment, and at each subsequent follow-up. Patients were followed for a total of 4 years or until disease progression or death, whichever came first. Data and safety monitoring was performed at least every 6 months.
The primary objective of the phase I portion of the study was to determine the maximum tolerated dose (MTD) of SBRT. The primary objective of the phase II portion of the study was to learn if the MTD determined in phase I achieves acceptable local control of more than 80% at 2 years. Local control was defined as the absence of failure within the primary tumor and involved lobe. The secondary objective of the phase II portion was to estimate the rates of regional nodal recurrence, disseminated recurrence, disease-free survival (DFS), and overall survival (OS) at 2 years.
Statistical Design
The phase I portion had a "5 þ 3" strategy with four escalating dose levels, only one of which was open for accrual at any time. Five patients were accrued to each dose level, and once closed, the next dose level could not be opened until the preceding dose was deemed acceptable. With a minimum of 90 days from the start of radiation therapy, if there were no acute grade 3 or 4 nonhematologic toxicities in the five patients, the current dose was deemed acceptable. If one such toxicity was observed, an additional three patients were recruited and followed for a minimum of 90 days. If two or more such toxicities were observed, the current dose was determined as dose limiting, and the previous dose level was used for the phase II portion. The phase II portion aimed to have a 2-year local control rate greater than 80%. Based on Fleming's single-stage design, at least 43 patients were calculated as needed during the phase II portion to detect an improvement in local control from 60% to 80% with 80% power at a 2-sided Type I error rate of 0.05.
Time-to-event data was calculated from the last fraction of SBRT and analyzed with Kaplan-Meier estimates. For analysis of the primary phase II objective of the local control rate at 2 years, patients who died within 2 years without failure in the involved lobe were censored at the time of last follow-up. For analysis of the secondary objectives of regional nodal and disseminated recurrence rates at 2 years, patients who died within 2 years without these respective disease recurrences were likewise censored at the time of last follow-up. An event for DFS was defined as the first of any of local failure, regional failure, disseminated failure, second primary, or death from any cause. Patients were otherwise censored at the time of last follow-up. For patients subsequently lost to follow-up, online obituaries were used to confirm death. We used the Kaplan-Meier product limit estimator with the log-rank test statistic for exploring differences between outcomes for squamous histology versus nonsquamous histology and for tumor size less than or equal 3 cm and greater than 3 cm.
Results
Phase I
Twenty-three patients with histologically proven central early-stage NSCLC were enrolled on the phase I portion of this trial. SBRT consisted of 5 fractions of 9, 10, 11, and 12 Gy each on cohorts A, B, C, and D, respectively. The mean (range) of follow-up duration for cohorts A (n ¼ 5), B (n ¼ 6), C (n ¼ 6), and D (n ¼ 5) are 22.9 (6 to 47), 25.3 (2 to 42), 17.3 (13 to 22), and 6.6 (1 to 11) months, respectively. Two patients treated to 10 Gy Â 5 fractions developed an unrelated grade 3 lung toxicity which resolved. One was hospitalized briefly at an outside hospital for dyspnea, and another was hospitalized for pneumonia. Neither required steroids after discharge. There were no other acute grade 3 or greater toxicities noted. One primary tumor failure occurred within cohort A. No local failures occurred within cohorts B, C, or D. Although the MTD in phase I was therefore 12 Gy per fraction, we made the decision to proceed with 11 Gy per fraction (cohort C) for the phase II portion. After the final patient in cohort C was treated, it took 16 months to accrue, treat, and follow all of cohort D for 90 days post-treatment. During this 16-month period, we observed excellent local control with 11 Gy per fraction and decided to proceed with it rather than risk more late toxicity with the phase I MTD. Phase II
Between December 2010 and July 2016, 51 patients were enrolled to phase II where they received 11 Gy per fraction for 5 fractions to their central tumors. Pretreatment characteristics of these patients are in Table 2 . The median age was 73 years, and the majority were white (n ¼ 42, 82%) with a Zubrod performance status of 1 (n ¼ 26, 51%) and a diagnosis of squamous cell carcinoma (n ¼ 31, 61%). Most tumors were located within 2 cm of proximal bronchial tree (n ¼ 43, 84%), with smaller numbers within 5 mm of the mediastinal pleura (n ¼ 6, 12%), and 5 mm of the parietal pericardium (n ¼ 2, 4%). The median follow-up was 17 months (range, 2 to 59 months) for all patients. Among patients still living (n ¼ 16), median follow-up was 27 months (range, 9 to 58 months). One patient did not return for follow-up evaluation and was excluded from analysis as no survival information could be obtained. One patient received chemotherapy against protocol at an outside institution in the month following treatment. Five patients on phase II were treated errantly with 10 Gy fractions, rather than 11 Gy fractions, but were included in the analysis. Figures 1 and 2 provide estimates of local control, progression-free, and overall survival. At 2 years, four patients failed locally at the treatment site. There were no marginal recurrences or isolated lobar failures. The 2-year local control rate was 85% (95% confidence interval [CI]: 62%-95%) (Fig. 1) , which met the primary phase II objective of improving the 2-year local control rate to greater than 80%. Two of these patients with treatment site failures were deemed too frail for systemic therapy or other interventions and went on hospice. One patient refused both further interventions and hospice. The fourth developed a second primary in a different lobe of the same lung and at the time of salvage pneumonectomy was found to have viable disease at the treated site on final pathology. This patient died of postoperative complications. A fifth patient failed locally at 3 years, was treated with anti-programmed death 1 immunotherapy, and is still alive. Local control did not differ between squamous versus other histology (p ¼ 0.26) or primary size greater than 3 cm (p ¼ 0.08).
There were no isolated regional nodal failures as all three nodal failures were found simultaneously with disseminated systemic recurrences. At 2 years, 10 patients failed with distant metastases for a 2-year disseminated recurrence rate of 27% (95% CI: 15%-45%). The 2-year disseminated recurrence rate for nonsquamous carcinoma was 42% (95% CI: 22%-68%) Figure 1 . Kaplan-Meier estimate of local control using 11 Gy Â 5 fractions for centrally located, early stage NSCLC. and 16% for squamous carcinoma (95% CI: 6%-43%) (p ¼ 0.05). Disseminated recurrence rates did not differ between primaries greater and less than 3 cm (p ¼ 0.10).
Ten patients (20%, 95% CI: 10%-34%) developed second primaries in the follow-up period. Seven were treated with additional courses of SBRT and two with surgical resection. One of these resections led to fatal postoperative complications as described previously. The 10th patient presented with locally advanced disease and did not follow-up further at our institution.
The 2-year OS rate was 43% (95% CI: 28%-57%), and the median OS was 19 months (95% CI: 17 to 31 months). This did not differ by squamous histology (p ¼ 0.33), but patients with large primaries had worse OS (p ¼ 0.03). For primaries 3 cm or smaller, the 2-year OS was 64% (95% CI: 39%-81%) and for primaries greater than 3 cm, the 2-year OS was 25% (95% CI: 11%-43%). The 2-year DFS rate was 28% (95% CI: 16%-42%), and the median DFS was 15 months (95% CI: 9 to 16 months). There was no difference in DFS by histology (p ¼ 0.38), but patients with large primaries 3 cm or greater had worse DFS (p ¼ 0.04).
Of the 50 phase II patients evaluable for treatment related acute toxicity ( 90 days from treatment), there was a 6% rate of grade 3 or greater toxicity (95% CI: 1%-17%). One patient was admitted with grade 3 pneumonitis. This patient received pemetrexed within 1 month after SBRT by an outside physician against protocol guidelines. One patient had grade 3 dehydration and malnutrition potentially related to treatment, but had been admitted for the same diagnoses before treatment. There was one grade 4 pulmonary event that required intubation at an outside hospital. There were no acute grade 5 toxicities.
There were 41 phase II patients evaluable for late toxicity (>90 days from treatment). Late Toxicities are provided in Table 3 . Eleven patients (27%, 95% CI: 14%-43%) experienced late grade 3 toxicities, and 5 patients (12%, 95% CI: 4%-26%) late grade 4 toxicities. One patient developed a myocardial infarction requiring invasive intervention, three developed pneumonias requiring intubation, and one a myocardial infarction requiring coronary artery bypass grafting and a separate hypoxic event requiring intubation. One patient (4%, 95% CI: 0%-13%) developed a grade 5 toxicity. This patient developed multifocal bronchial stenosis requiring airway debridement and balloon dilation 10 months after treatment and developed fatal hemoptysis 17 months after treatment. This patient was recurrence free at the time. There were no grade 3 esophageal toxicities using a constraint of a 30-Gy maximum dose, which only two patients exceeded.
Discussion
This prospective study shows that for medically inoperable patients with early-stage NSCLC centrally located within 2 cm of the proximal bronchial tree, treatment with SBRT in 5 fractions of 11 Gy each resulted in a 2-year local control of 85%. This is markedly higher than that expected with conventional fractionation, but lower than the 98% rate of primary tumor control at 3 years seen in RTOG 0236 for more peripheral tumors. 6 The higher rate of local control on RTOG 0236 is likely due to its higher biologically effective dose of 3 fractions of 18 Gy that can be safely delivered for peripheral tumors located far from the main airways and cardiovascular structures.
There have been other retrospective reports on central lung SBRT that have shown similar rates of local control. Chaudhuri et al. 7 reported 90% to 100% local control of 34 central and "ultracentral" lung cancers treated to 50 Gy total in 4 to 5 fractions. Davis et al. 8 reported on 48 centrally located primary lung cancers treated in 1 to 5 fractions in an international database with a 2-year local control of 76.4%. Other hypofractionated regimens have also been reported retrospectively for central tumors. Chang et al. 9 treated 100 centrally located or recurrent NSCLC tumors in 10 fractions of 7 Gy each and showed a local control rate of 97% at 3 years. Haasbeek et al. 10 treated 63 patients with 8 fractions of 7.5 Gy each and showed a local control rate of 93% at 3 years.
The rates of acute and late toxicity in our prospective trial are higher than that seen in these retrospective reviews. Chaudhuri et al. 7 and Davis et al. 8 reported no grade 3 or higher acute or late toxicities. Chang et al. 9 reported a 1% rate of grade 3 pneumonitis and no grade 4 or 5 toxicities. Haasbeek et al. 10 had two patients each with grade 3 dyspnea and chest wall pain in their 63 patients. They reported no grade 4 or 5 toxicity, but "grade 5 toxicity could not be excluded with certainty in nine patients who died of cardiopulmonary causes." This uncertainty is understandable in the medically inoperable patient population with significant cardiac and pulmonary comorbidities. Many of our reported toxicities could have been unrelated exacerbations of underlying cardiac and pulmonary disease, but we erred on the side of attributing them to treatment as many involved hospitalizations at outside facilities. RTOG 0236 for peripheral lesions showed a 13% rate of grade 3 toxicities and 4% rate of grade 4 events but no grade 5 events. We showed a 27% rate of late grade 3 toxicities, a 12% rate of late grade 4 events, and a single grade 5 event. This was hemoptysis after SBRT with subsequent airway debridement and balloon dilation. This patient's proximal bronchial tree and great vessels both received in excess of prescription dose, but so did approximately two-thirds of the patients, and we cannot explain it with dosimetry at this time.
Our study aligns with other literature that suggests increasing tumor size is associated with worse rates of DFS and OS. 11 For patients with central tumors 3 cm in size or smaller, we showed a 2-year OS of 64%, whereas those with larger central tumors had a 2-year OS of 25% (p ¼ 0.03). Our study did not show a statistically significant difference in local failure due to size (p ¼ 0.08) or histology (p ¼ 0.26), but it was not powered for this comparison. Others have reported that larger tumors and squamous cell carcinomas have higher rates of local failure. 12, 13 In addition to the differences in doses used on RTOG 0236, the higher local control on RTOG 0236 could also be due to the fact that it enrolled patients with smaller primaries; 80% of its patients had tumors less than or equal to 3 cm. In contrast, 55% of patients on our trial had tumors larger than 3 cm, and 16% greater than 5 cm.
Strengths of this study include its prospective nature. Limitations include the fact that all toxicity outcomes were physician scored and there are no patient-reported outcomes. It being conducted at a single institution allowed for central review of all trial aspects can be deemed a strength but potentially limits its applicability to other institutions. Another limitation is that 9 of the 51 phase II patients were lost to long-term follow-up, and 5 of the 51 patients were treated with 10 Gy per fraction errantly rather than 11 Gy. However, there were no local failures in this lower dose cohort and only 1 failed distantly, which is comparable to the results in the overall phase II cohort.
Conclusion
SBRT can be used to effectively treat central NSCLC. The local control at 2 years after using 5 stereotactic fractions of 11 Gy each is 85%. This treatment is associated with increased rates of late toxicity, however, when compared to treatment of peripheral lesions. Patients with larger central tumors have worse rates of DFS and OS after treatment. We look forward to comparing our local control and toxicity with the results of RTOG 0813 which has completed accrual.
